• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

    5/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance
    Get the next $SLQT alert in real time by email

    Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights

    • Revenue of $430.9 million
    • Net income of $40.2 million
    • Adjusted EBITDA* of $44.6 million

    Fiscal Year 2026 Guidance Ranges:

    • Revenue expected in a range of $1.61 billion to $1.71 billion
    • Adjusted EBITDA* expected in a range of $90 million to $100 million

    Third Quarter Fiscal Year 2026 – Segment Highlights

    Senior

    • Revenue of $182.9 million
    • Adjusted EBITDA of $58.6 million
    • Approved Medicare Advantage policies of 175,557

    Healthcare Services

    • Revenue of $199.4 million
    • Adjusted EBITDA of $5.3 million
    • 116,616 SelectRx members

    Life

    • Revenue of $47.9 million
    • Adjusted EBITDA of $6.1 million

    SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the third quarter of fiscal year 2026 of $430.9 million compared to consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million. Consolidated net income for the third quarter of fiscal year 2026 was $40.2 million compared to consolidated net income for the third quarter of fiscal year 2025 of $26.0 million. Finally, consolidated Adjusted EBITDA* for the third quarter of fiscal year 2026 was $44.6 million compared to consolidated Adjusted EBITDA* for the third quarter of fiscal year 2025 of $37.7 million.

    SelectQuote Chief Executive Officer Tim Danker remarked, "SelectQuote delivered consistent profit and cash flow for another quarter, despite market shifts for both Medicare Advantage and prescription drugs. We reaffirm our financial outlook for fiscal 2026 driven by operating execution by our agents and continued leverage of our information and technology advantages. Revenue to customer acquisition cost of 6.7X represented a high water mark for the company, and more importantly, signals the value our differentiated healthcare service model provides to policyholders and prescription drug customers."

    Mr. Danker continued, "Our goal to drive reliable and consistent profit, and cash flow growth remains priority number one. We believe the improvement to our capital structure to date, combined with the continued maturation of our SelectRx business, positions SelectQuote to materially expand cash flow in the years ahead. We continue to grow our receivables balance, which now stands at nearly $1 billion and grew by nearly $50 million over the past year, including a $14 million positive change in estimate reflective of the durability and dependability of these future cash flows."

    * See "Non-GAAP Financial Measures" below.

    Segment Results

    We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.

    Senior

    Financial Results

    The following table provides the financial results for the Senior segment for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

    (in thousands)

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Revenue

    $

    182,890

     

     

    $

    169,442

     

     

    8

    %

    $

    503,426

     

     

    $

    517,930

     

     

    (3

    )%

    Adjusted EBITDA

     

    58,642

     

     

     

    45,701

     

     

    28

    %

     

    140,057

     

     

     

    153,949

     

     

    (9

    )%

    Adjusted EBITDA Margin

     

    32

    %

     

     

    27

    %

     

     

     

    28

    %

     

     

    30

    %

     

     

    Operating Metrics

    Submitted Policies

    Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

    The following table shows the number of submitted policies for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

     

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Medicare Advantage

    196,970

     

    201,817

     

    (2

    )%

    553,286

     

    588,872

     

    (6

    )%

    All other (1)

    24,912

     

    22,858

     

    9

    %

    71,632

     

    65,975

     

    9

    %

    Total

    221,882

     

    224,675

     

    (1

    )%

    624,918

     

    654,847

     

    (5

    )%

    (1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Approved Policies

    Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

    The following table shows the number of approved policies for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

     

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Medicare Advantage

    175,557

     

    168,001

     

    4

    %

    495,346

     

    507,530

     

    (2

    )%

    All other (1)

    21,152

     

    17,623

     

    20

    %

    55,330

     

    50,316

     

    10

    %

    Total

    196,709

     

    185,624

     

    6

    %

    550,676

     

    557,846

     

    (1

    )%

    (1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Lifetime Value of Commissions per Approved Policy

    Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

    The following table shows the lifetime value of commissions per approved policy for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

    (dollars per policy):

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Medicare Advantage

    $

    904

     

    $

    915

     

    (1

    )%

    $

    871

     

    $

    892

     

    (2

    )%

    All other(1)

     

    81

     

     

    151

     

    (46

    )%

     

    121

     

     

    139

     

    (13

    )%

    (1) Represents the weighted average LTV per approved policy.

    Healthcare Services

    Financial Results

    The following table provides the financial results for the Healthcare Services segment for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

    (in thousands)

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Revenue

    $

    199,386

     

     

    $

    189,569

     

     

    5

    %

    $

    651,391

     

     

    $

    528,677

     

     

    23

    %

    Adjusted EBITDA

     

    5,278

     

     

     

    6,445

     

     

    (18

    )%

     

    13,336

     

     

     

    13,534

     

     

    (1

    )%

    Adjusted EBITDA Margin

     

    3

    %

     

     

    3

    %

     

     

     

    2

    %

     

     

    3

    %

     

     

    Operating Metrics

    Members

    The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

    The following table shows the total number of SelectRx members as of the periods presented:

     

     

    March 31, 2026

     

    March 31, 2025

    Total SelectRx Members

     

    116,616

     

    105,523

    The total number of SelectRx members increased by 11% as of March 31, 2026, compared to March 31, 2025, due to our strategy to grow SelectRx membership.

    The following table shows the average prescriptions shipped per day for the periods presented:

     

     

    Three Months Ended March 31,

     

    Nine Months Ended March 31,

     

     

    2026

     

    2025

     

    2026

     

    2025

    Prescriptions Per Day

     

    33,209

     

    29,015

     

    32,384

     

    26,942

    Combined Senior and Healthcare Services - Consumer Per Unit Economics

    Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

    The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

    The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

     

    Twelve Months Ended March 31,

    (dollars per approved policy):

    2026

     

    2025

    MA and MS approved policies

     

    582,951

     

     

     

    616,379

     

    MA and MS commission per MA / MS policy

    $

    868

     

     

    $

    885

     

    Other commission per MA/MS policy

     

    11

     

     

     

    13

     

    Pharmacy revenue per MA/MS policy

     

    1,461

     

     

     

    1,063

     

    Other revenue per MA/MS policy

     

    150

     

     

     

    103

     

    Total revenue per MA / MS policy

     

    2,490

     

     

     

    2,064

     

    Total operating expenses per MA / MS policy

     

    (2,193

    )

     

     

    (1,794

    )

    Adjusted EBITDA per MA/MS policy

    $

    297

     

     

    $

    270

     

    Adjusted EBITDA Margin per MA/MS policy

     

    12

    %

     

     

    13

    %

    Revenue / CAC multiple

    6.7X

     

    5.8X

    Total revenue per MA/MS policy increased 21% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 22% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

    Life

    Financial Results

    The following table provides the financial results for the Life segment for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

    (in thousands)

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Revenue

    $

    47,896

     

     

    $

    45,842

     

     

    4

    %

    $

    138,166

     

     

    $

    124,993

     

     

    11

    %

    Adjusted EBITDA

     

    6,084

     

     

     

    6,364

     

     

    (4

    )%

     

    17,236

     

     

     

    19,747

     

     

    (13

    )%

    Adjusted EBITDA Margin

     

    13

    %

     

     

    14

    %

     

     

     

    13

    %

     

     

    16

    %

     

     

    Operating Metrics

    Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

    The following table shows term and final expense premiums for the periods presented:

     

    Three Months Ended March 31,

     

     

    Nine Months Ended March 31,

     

     

    (in thousands)

    2026

     

    2025

     

    % Change

    2026

     

    2025

     

    % Change

    Term Premiums

    $

    19,123

     

    $

    18,930

     

    1

    %

     

    $

    56,079

     

    $

    51,459

     

    9

    %

    Final Expense Premiums

     

    27,287

     

     

    27,681

     

    (1

    )%

     

     

    84,072

     

     

    74,292

     

    13

    %

    Total

    $

    46,410

     

    $

    46,611

     

    —

    %

     

    $

    140,151

     

    $

    125,751

     

    11

    %

    Earnings Conference Call

    SelectQuote, Inc. will host a conference call with the investment community on May 5, 2026 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://events.q4inc.com/analyst/775360431?pwd=VqmW7XWK. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

    Non-GAAP Financial Measures

    This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

    A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income, is presented below on page 15. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.

    Forward Looking Statements

    This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

    About SelectQuote:

    Founded in 1985, SelectQuote (NYSE:SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

    With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (In thousands)

     

     

    March 31, 2026

     

    June 30, 2025

    ASSETS

     

     

     

    CURRENT ASSETS:

     

     

     

    Cash, cash equivalents, and restricted cash

    $

    35,211

     

     

    $

    35,733

     

    Accounts receivable, net of allowances of $9.2 million and $11.8 million, respectively

     

    234,291

     

     

     

    151,388

     

    Commissions receivable-current

     

    76,836

     

     

     

    132,077

     

    Other current assets

     

    20,900

     

     

     

    21,844

     

    Total current assets

     

    367,238

     

     

     

    341,042

     

    COMMISSIONS RECEIVABLE—Net

     

    882,693

     

     

     

    818,751

     

    PROPERTY AND EQUIPMENT—Net

     

    13,247

     

     

     

    14,577

     

    SOFTWARE—Net

     

    16,953

     

     

     

    15,060

     

    OPERATING LEASE RIGHT-OF-USE ASSETS

     

    21,566

     

     

     

    24,635

     

    INTANGIBLE ASSETS—Net

     

    1,120

     

     

     

    1,973

     

    GOODWILL

     

    29,438

     

     

     

    29,438

     

    OTHER ASSETS

     

    2,455

     

     

     

    3,880

     

    TOTAL ASSETS

    $

    1,334,710

     

     

    $

    1,249,356

     

     

     

     

     

    LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

     

     

     

    CURRENT LIABILITIES:

     

     

     

    Accounts payable

    $

    103,205

     

     

    $

    59,205

     

    Accrued expenses

     

    24,092

     

     

     

    13,856

     

    Accrued compensation and benefits

     

    68,646

     

     

     

    58,788

     

    Operating lease liabilities—current

     

    4,665

     

     

     

    4,820

     

    Current portion of long-term debt

     

    22,457

     

     

     

    68,523

     

    Other current liabilities

     

    8,035

     

     

     

    7,718

     

    Total current liabilities

     

    231,100

     

     

     

    212,910

     

    LONG-TERM DEBT, NET—less current portion

     

    353,326

     

     

     

    316,589

     

    DEFERRED INCOME TAXES

     

    45,211

     

     

     

    37,872

     

    OPERATING LEASE LIABILITIES

     

    22,678

     

     

     

    25,982

     

    OTHER LIABILITIES

     

    18,904

     

     

     

    80,485

     

    Total liabilities

     

    671,219

     

     

     

    673,838

     

     

     

     

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

    PREFERRED STOCK:

     

     

     

    Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively, current liquidation preference of $408.4 million and $367.1 million as of March 31, 2026 and June 30, 2025.

     

    278,757

     

     

     

    224,374

     

    SHAREHOLDERS' EQUITY:

     

     

     

    Common stock, $0.01 par value

     

    1,763

     

     

     

    1,728

     

    Additional paid-in capital

     

    526,129

     

     

     

    571,605

     

    Accumulated deficit

     

    (143,158

    )

     

     

    (222,189

    )

    Total shareholders' equity

     

    384,734

     

     

     

    351,144

     

    TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

    $

    1,334,710

     

     

    $

    1,249,356

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (Unaudited)

    (In thousands)

     

     

    Three Months Ended March 31,

     

    Nine Months Ended March 31,

     

    2026

     

    2025

     

    2026

     

    2025

    REVENUE:

     

     

     

     

     

     

     

    Commissions and other services

    $

    235,663

     

     

    $

    222,889

     

     

    $

    655,823

     

     

    $

    663,338

     

    Pharmacy

     

    195,270

     

     

     

    185,271

     

     

     

    641,023

     

     

     

    518,154

     

    Total revenue

     

    430,933

     

     

     

    408,160

     

     

     

    1,296,846

     

     

     

    1,181,492

     

     

     

     

     

     

     

     

     

    OPERATING COSTS AND EXPENSES:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    83,268

     

     

     

    79,412

     

     

     

    255,403

     

     

     

    246,283

     

    Cost of goods sold—pharmacy revenue

     

    171,289

     

     

     

    162,304

     

     

     

    569,262

     

     

     

    448,029

     

    Marketing and advertising

     

    92,481

     

     

     

    92,733

     

     

     

    259,456

     

     

     

    254,222

     

    Selling, general, and administrative

     

    38,188

     

     

     

    41,685

     

     

     

    112,948

     

     

     

    122,850

     

    Technical development

     

    9,777

     

     

     

    9,967

     

     

     

    29,283

     

     

     

    29,086

     

    Total operating costs and expenses

     

    395,003

     

     

     

    386,101

     

     

     

    1,226,352

     

     

     

    1,100,470

     

     

     

     

     

     

     

     

     

    INCOME FROM OPERATIONS

     

    35,930

     

     

     

    22,059

     

     

     

    70,494

     

     

     

    81,022

     

     

     

     

     

     

     

     

     

    INTEREST EXPENSE, NET

     

    (10,602

    )

     

     

    (20,407

    )

     

     

    (34,023

    )

     

     

    (67,160

    )

    CHANGE IN FAIR VALUE OF WARRANTS

     

    27,489

     

     

     

    32,986

     

     

     

    61,821

     

     

     

    25,344

     

    LOSS ON EXTINGUISHMENT OF DEBT

     

    (8,659

    )

     

     

    —

     

     

     

    (8,659

    )

     

     

    —

     

    OTHER EXPENSE, NET

     

    (34

    )

     

     

    (37

    )

     

     

    (216

    )

     

     

    (70

    )

    INCOME BEFORE INCOME TAX EXPENSE

     

    44,124

     

     

     

    34,601

     

     

     

    89,417

     

     

     

    39,136

     

    INCOME TAX EXPENSE

     

    3,927

     

     

     

    8,579

     

     

     

    10,386

     

     

     

    4,424

     

     

     

     

     

     

     

     

     

    NET INCOME

    $

    40,197

     

     

    $

    26,022

     

     

    $

    79,031

     

     

    $

    34,712

     

    Senior Non-Convertible Preferred Stock accumulated dividends and accretion

     

    (18,775

    )

     

     

    (5,787

    )

     

    (54,382

    )

     

    (5,787

    )

    NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS

    $

    21,422

     

     

    $

    20,235

     

     

    $

    24,649

     

     

    $

    28,925

     

     

     

     

     

     

     

     

     

    NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

     

     

     

     

     

     

     

    Basic

    $

    0.11

     

     

    $

    0.11

     

     

    $

    0.13

     

     

    $

    0.17

     

    Diluted

    $

    0.11

     

     

    $

    0.03

     

     

    $

    0.11

     

     

    $

    0.13

     

     

     

     

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

     

     

     

     

     

     

     

    Basic

     

    189,455

     

     

     

    178,156

     

     

     

    187,614

     

     

     

    173,462

     

    Diluted

     

    190,481

     

     

     

    186,639

     

     

     

    190,647

     

     

     

    178,895

     

     

     

     

     

     

     

     

     

    OTHER COMPREHENSIVE LOSS, NET OF TAX:

     

     

     

     

     

     

     

    Unrealized loss, net of related tax benefit for the three and nine months ended March 31, 2026, and 2025, of $0.0 million and $0.1 million

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (432

    )

    Amount reclassified into earnings, net of related tax benefit for the three months ended March 31, 2026, and 2025, of $0.0 million, and $0.0 million and for the nine months ended March 31, 2026, and 2025, of $0.0 million and $1.3 million.

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (3,680

    )

    OTHER COMPREHENSIVE LOSS

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (4,112

    )

    COMPREHENSIVE INCOME

    $

    40,197

     

     

    $

    26,022

     

     

    $

    79,031

     

     

    $

    30,600

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

    (In thousands)

     

     

    Nine Months Ended March 31,

     

    2026

     

    2025

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

    Net income

    $

    79,031

     

     

    $

    34,712

     

    Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    13,007

     

     

     

    15,584

     

    Loss on disposal of property, equipment, and software

     

    —

     

     

     

    160

     

    Impairment of equity-method investment

     

    1,000

     

     

     

    —

     

    Loss on extinguishment of debt

     

    8,659

     

     

     

    —

     

    Share-based compensation expense

     

    11,480

     

     

     

    13,505

     

    Deferred income taxes

     

    7,340

     

     

     

    4,424

     

    Amortization of debt issuance costs and debt discount

     

    3,343

     

     

     

    3,880

     

    Write-off of debt issuance costs

     

    —

     

     

     

    93

     

    Accrued interest payable in kind

     

    —

     

     

     

    13,301

     

    Change in fair value of warrants

     

    (61,821

    )

     

     

    (25,344

    )

    Non-cash lease expense

     

    3,070

     

     

     

    2,849

     

    Bad debt expense

     

    —

     

     

     

    4,203

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable, net

     

    (82,903

    )

     

     

    (39,047

    )

    Commissions receivable

     

    (8,702

    )

     

     

    (33,765

    )

    Other assets

     

    1,261

     

     

     

    (343

    )

    Accounts payable and accrued expenses

     

    53,583

     

     

     

    41,163

     

    Operating lease liabilities

     

    (3,459

    )

     

     

    (3,574

    )

    Other liabilities

     

    10,315

     

     

     

    (5,985

    )

    Net cash provided by operating activities

     

    35,204

     

     

     

    25,816

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

    Purchases of property and equipment

     

    (3,093

    )

     

     

    (1,690

    )

    Purchases of software and capitalized software development costs

     

    (8,490

    )

     

     

    (6,513

    )

    Net cash used in investing activities

     

    (11,583

    )

     

     

    (8,203

    )

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

    Proceeds from revolving credit facility

     

    270,000

     

     

     

    166,900

     

    Payments on revolving credit facility

     

    (270,000

    )

     

     

    (166,900

    )

    Net proceeds from Term Loan

     

    315,234

     

     

     

    —

     

    Payments on Term Loans

     

    (314,000

    )

     

     

    (384,644

    )

    Proceeds from ABS Notes

     

    —

     

     

     

    99,095

     

    Payments on ABS Notes

     

    (15,016

    )

     

     

    (11,723

    )

    Payments on other debt

     

    (380

    )

     

     

    (202

    )

    Proceeds from common stock options exercised and employee stock purchase plan

     

    —

     

     

     

    112

     

    Proceeds from issuance of Senior Non-Convertible Preferred Stock

     

    —

     

     

     

    337,855

     

    Senior Non-Convertible Preferred Stock issuance costs

     

    —

     

     

     

    (7,076

    )

    Payments of tax withholdings related to net share settlement of equity awards

     

    (2,539

    )

     

     

    (5,019

    )

    Payments of debt issuance costs

     

    (7,730

    )

     

     

    (2,479

    )

    Net cash (used in) provided by financing activities

     

    (24,431

    )

     

     

    25,919

     

    NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

    (810

    )

     

     

    43,532

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period

     

    37,066

     

     

     

    42,690

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period

    $

    36,256

     

     

    $

    86,222

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense

    (Unaudited)

     

     

    Three Months Ended March 31, 2026

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    182,890

     

     

    $

    199,386

     

     

    $

    47,896

     

     

    $

    430,172

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (54,596

    )

     

     

    (6,976

    )

     

     

    (18,465

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (169,814

    )

     

     

    —

     

     

     

    Marketing expense

     

    (69,060

    )

     

     

    (1,686

    )

     

     

    (23,131

    )

     

     

    Technical development

     

    —

     

     

     

    (318

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (592

    )

     

     

    (15,314

    )

     

     

    (216

    )

     

     

    Adjusted Segment EBITDA

    $

    58,642

     

     

    $

    5,278

     

     

    $

    6,084

     

     

    $

    70,004

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    1,376

     

    Corporate

     

     

     

     

     

     

     

    (26,790

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (3,678

    )

    Transaction costs

     

     

     

     

     

     

     

    (631

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (4,385

    )

    Loss on extinguishment of debt

     

     

     

     

     

     

     

    (8,659

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    27,489

     

    Interest expense, net

     

     

     

     

     

     

     

    (10,602

    )

    Income before income tax expense

     

     

     

     

     

     

    $

    44,124

     

     

    Three Months Ended March 31, 2025

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    169,442

     

     

    $

    189,569

     

     

    $

    45,842

     

     

    $

    404,853

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (53,374

    )

     

     

    (5,816

    )

     

     

    (17,415

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (161,026

    )

     

     

    —

     

     

     

    Marketing expense

     

    (69,808

    )

     

     

    (1,939

    )

     

     

    (21,789

    )

     

     

    Technical development

     

    —

     

     

     

    (491

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (559

    )

     

     

    (13,852

    )

     

     

    (274

    )

     

     

    Adjusted Segment EBITDA

    $

    45,701

     

     

    $

    6,445

     

     

    $

    6,364

     

     

    $

    58,510

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    3,549

     

    Corporate

     

     

     

     

     

     

     

    (24,336

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (4,960

    )

    Transaction costs

     

     

     

     

     

     

     

    (5,813

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (4,925

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (3

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    32,986

     

    Interest expense, net

     

     

     

     

     

     

     

    (20,407

    )

    Income before income tax expense

     

     

     

     

     

     

    $

    34,601

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense

    (Unaudited)

     

     

    Nine Months Ended March 31, 2026

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    503,426

     

     

    $

    651,391

     

     

    $

    138,166

     

     

    $

    1,292,983

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (170,884

    )

     

     

    (21,635

    )

     

     

    (53,848

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (564,995

    )

     

     

    —

     

     

     

    Marketing expense

     

    (190,746

    )

     

     

    (6,309

    )

     

     

    (66,267

    )

     

     

    Technical development

     

    —

     

     

     

    (1,068

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (1,739

    )

     

     

    (44,048

    )

     

     

    (815

    )

     

     

    Adjusted Segment EBITDA

    $

    140,057

     

     

    $

    13,336

     

     

    $

    17,236

     

     

    $

    170,629

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    5,366

     

    Corporate

     

     

     

     

     

     

     

    (78,752

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (11,480

    )

    Transaction costs

     

     

     

     

     

     

     

    (1,478

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (13,007

    )

    Impairment of equity-method investment

     

     

     

     

     

     

     

    (1,000

    )

    Loss on extinguishment of debt

     

     

     

     

     

     

     

    (8,659

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    61,821

     

    Interest expense, net

     

     

     

     

     

     

     

    (34,023

    )

    Income before income tax expense

     

     

     

     

     

     

    $

    89,417

     

     

    Nine Months Ended March 31, 2025

    (in thousands)

    Senior

     

    Healthcare Services

     

    Life

     

    Total

    Total revenue from reportable segments

    $

    517,930

     

     

    $

    528,677

     

     

    $

    124,993

     

     

    $

    1,171,600

     

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (169,543

    )

     

     

    (19,627

    )

     

     

    (47,028

    )

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

     

    (444,401

    )

     

     

    —

     

     

     

    Marketing expense

     

    (192,583

    )

     

     

    (6,088

    )

     

     

    (57,456

    )

     

     

    Technical development

     

    —

     

     

     

    (1,691

    )

     

     

    —

     

     

     

    Selling, general, and administrative

     

    (1,855

    )

     

     

    (43,336

    )

     

     

    (762

    )

     

     

    Adjusted Segment EBITDA

    $

    153,949

     

     

    $

    13,534

     

     

    $

    19,747

     

     

    $

    187,230

     

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    9,645

     

    Corporate

     

     

     

     

     

     

     

    (73,316

    )

    Share-based compensation expense

     

     

     

     

     

     

     

    (13,505

    )

    Transaction costs

     

     

     

     

     

     

     

    (13,358

    )

    Depreciation and amortization

     

     

     

     

     

     

     

    (15,584

    )

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (160

    )

    Change in fair value of warrants

     

     

     

     

     

     

     

    25,344

     

    Interest expense, net

     

     

     

     

     

     

     

    (67,160

    )

    Income before income tax expense

     

     

     

     

     

     

    $

    39,136

     

    RECONCILIATION OF NON-GAAP MEASURE

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation of Net income to Adjusted EBITDA

    (Unaudited)

     

     

    Three Months Ended March 31,

     

    Nine Months Ended March 31,

    (in thousands)

    2026

     

    2025

     

    2026

     

    2025

    Net income

    $

    40,197

     

     

    $

    26,022

     

     

    $

    79,031

     

     

    $

    34,712

     

    Share-based compensation expense

     

    3,678

     

     

     

    4,960

     

     

     

    11,480

     

     

     

    13,505

     

    Transaction costs

     

    631

     

     

     

    5,813

     

     

     

    1,478

     

     

     

    13,358

     

    Depreciation and amortization

     

    4,385

     

     

     

    4,925

     

     

     

    13,007

     

     

     

    15,584

     

    Loss on disposal of property, equipment, and software, net

     

    —

     

     

     

    3

     

     

     

    —

     

     

     

    160

     

    Impairment of equity-method investment

     

    —

     

     

     

    —

     

     

     

    1,000

     

     

     

    —

     

    Loss on extinguishment of debt

     

    8,659

     

     

     

    —

     

     

     

    8,659

     

     

     

    —

     

    Change in fair value of warrants

     

    (27,489

    )

     

     

    (32,986

    )

     

     

    (61,821

    )

     

     

    (25,344

    )

    Interest expense, net

     

    10,602

     

     

     

    20,407

     

     

     

    34,023

     

     

     

    67,160

     

    Income tax expense

     

    3,927

     

     

     

    8,579

     

     

     

    10,386

     

     

     

    4,424

     

    Adjusted EBITDA

    $

    44,590

     

     

    $

    37,723

     

     

    $

    97,243

     

     

    $

    123,559

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260505838568/en/

    Investor Relations:

    Sloan Bohlen

    877-678-4083

    investorrelations@selectquote.com

    Media:

    Matt Gunter

    913-286-4931

    matt.gunter@selectquote.com

    Get the next $SLQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLQT

    DatePrice TargetRatingAnalyst
    5/21/2025$2.75Hold
    Jefferies
    9/30/2024$4.50Buy
    Craig Hallum
    2/29/2024$5.00Outperform
    Noble Capital Markets
    4/1/2022$4.00Neutral
    Credit Suisse
    2/8/2022$9.00 → $5.00Equal Weight
    Barclays
    2/8/2022$13.00 → $3.00Sector Perform
    RBC Capital
    2/8/2022$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    2/8/2022$14.00 → $4.00Outperform → Neutral
    Credit Suisse
    More analyst ratings

    $SLQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on SelectQuote with a new price target

    Jefferies initiated coverage of SelectQuote with a rating of Hold and set a new price target of $2.75

    5/21/25 8:59:27 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Craig Hallum initiated coverage on SelectQuote with a new price target

    Craig Hallum initiated coverage of SelectQuote with a rating of Buy and set a new price target of $4.50

    9/30/24 8:47:10 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Noble Capital Markets initiated coverage on SelectQuote with a new price target

    Noble Capital Markets initiated coverage of SelectQuote with a rating of Outperform and set a new price target of $5.00

    2/29/24 8:29:44 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT Grant Robert Clay bought $105,024 worth of shares (118,901 units at $0.88) (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    2/19/26 4:11:41 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Director Devine Denise L bought $14,460 worth of shares (4,000 units at $3.62), increasing direct ownership by 1% to 318,583 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/19/25 4:54:26 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Matthews Joshua Brandon bought $113,295 worth of shares (97,500 units at $1.16), increasing direct ownership by 32% to 400,937 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:29:01 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SelectQuote Announces Participation in Upcoming RBC Global Healthcare Conference on May 20

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, announced today that Chief Financial Officer, Ryan Clement, and Head of Investor Relations, Matt Gunter, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, beginning at approximately 11:00am ET. Management will also be available for 1x1 and small group investor meetings. About SelectQuote Founded in 1985, SelectQuote (NYSE:SLQT) pioneered the model of providing unbiased comparisons from multiple, highly rated insurance companies, allowing consumers to choose the policy and ter

    5/14/26 4:15:00 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

    Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $430.9 million Net income of $40.2 million Adjusted EBITDA* of $44.6 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Third Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $182.9 million Adjusted EBITDA of $58.6 million Approved Medicare Advantage policies of 175,557 Healthcare Services Revenue of $199.4 million Adjusted EBITDA of $5.3 million 116,616 SelectRx members Life Revenue of $47.9 million Adjusted EBITDA of $6.1 mi

    5/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing healthcare services platform, today announced it will release its fiscal third quarter 2026 financial results before market open on Tuesday, May 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (May 5, 2026) at 8:30 am ET to discuss the results. We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link. For those interested in dialing into the conference call, ple

    4/21/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    SEC Filings

    View All

    SEC Form 144 filed by SelectQuote Inc.

    144 - SelectQuote, Inc. (0001794783) (Subject)

    5/19/26 4:40:05 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 10-Q filed by SelectQuote Inc.

    10-Q - SelectQuote, Inc. (0001794783) (Filer)

    5/5/26 4:06:37 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SelectQuote, Inc. (0001794783) (Filer)

    5/5/26 7:24:01 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devine Denise L sold $4,080 worth of shares (4,000 units at $1.02), decreasing direct ownership by 1% to 367,214 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    5/21/26 5:02:22 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Director Wolfe Chris converted options into 9,502 shares (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/3/26 7:00:55 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Chief Financial Officer Clement Ryan Moore converted options into 27,068 shares and covered exercise/tax liability with 9,380 shares, increasing direct ownership by 6% to 322,393 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/3/26 6:23:16 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Leadership Updates

    Live Leadership Updates

    View All

    SelectQuote Names Ryan Clement as Chief Financial Officer

    Clement has served as Interim CFO since May 2022 SelectQuote, Inc. (NYSE:SLQT) today announced that the Board of Directors appointed Ryan Clement, SVP of Financial Planning & Analysis, to serve as the company's Chief Financial Officer. Clement was named interim CFO in May 2022. CEO Tim Danker commented, "Over the last year, Ryan has excelled as our Interim CFO and has demonstrated both the financial acumen and leadership qualities we are looking for in the company's next permanent CFO. Ryan has played a critical role in our strategic redesign that has vastly improved SelectQuote's operating results and financial stability and positions the company to execute on our objectives in the futur

    2/22/23 8:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Financials

    Live finance-specific insights

    View All

    SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

    Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $430.9 million Net income of $40.2 million Adjusted EBITDA* of $44.6 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Third Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $182.9 million Adjusted EBITDA of $58.6 million Approved Medicare Advantage policies of 175,557 Healthcare Services Revenue of $199.4 million Adjusted EBITDA of $5.3 million 116,616 SelectRx members Life Revenue of $47.9 million Adjusted EBITDA of $6.1 mi

    5/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Third Quarter 2026 Earnings on May 5

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing healthcare services platform, today announced it will release its fiscal third quarter 2026 financial results before market open on Tuesday, May 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (May 5, 2026) at 8:30 am ET to discuss the results. We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link. For those interested in dialing into the conference call, ple

    4/21/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results

    Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $537.1 million Net income of $69.3 million Adjusted EBITDA* of $84.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Second Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $261.5 million Adjusted EBITDA of $102.5 million Approved Medicare Advantage policies of 257,279 Healthcare Services Revenue of $230.7 million Adjusted EBITDA of $0.8 million 113,483 SelectRx members Life Revenue of $43.6 million Adjusted EBITDA of $5.6

    2/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    1/29/24 3:26:24 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/14/23 1:42:28 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/1/23 4:54:05 PM ET
    $SLQT
    Specialty Insurers
    Finance